During the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress in London, new data highlighted the importance of continuing urate-lowering therapy (ULT) during remission for gout patients. A randomized trial involving 309 participants revealed that 79.2% of those who continued ULT met remission criteria, compared to only 62.9% in the discontinuation group. Furthermore, the cumulative flare incidence was significantly lower at 12.3% for those on continuous treatment, versus 31.8% for those who attempted to stop. The study also noted that 23% of patients who discontinued ULT required to restart treatment after a median of 392 days. Iris Rose Peeters, who presented the findings, emphasized the need for ongoing ULT to maintain remission and suggested focusing on long-term outcomes and predictors of successful discontinuation. Additionally, research presented at the congress indicated that obesity contributes to adverse body fat distribution, increasing the risk of gout and rheumatoid arthritis, which underscores the importance of weight management and physical activity as part of treatment strategies.